EliteImmune
EliteImmune is a private Gaithersburg, Maryland- and Tianjin, China-based biotechnology company that discovers broadly neutralizing antibody therapeutics for infectious diseases, oncology, and aging using its proprietary CellProbe™ and CellSeq™ single B cell screening and bioinformatics platforms, and monetizes those platforms through CRO services and reagent sales via its EliteImmune Bioservices subsidiary.
- Company typePrivate
- Founded2019
- HeadquartersGaithersburg, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What EliteImmune does
EliteImmune is a privately held biotechnology company founded in 2019 by Xuelian Zhao, Ph.D., headquartered in Gaithersburg, Maryland, with a parallel China headquarters (天津翊礼生物医药有限公司) in the Tianjin Eco-city BioHealth Valley. The company operates a dual R&D engine focused on the discovery and development of broadly neutralizing antibody (bNAb) therapeutics for infectious diseases, with secondary programs in oncology and aging. Its core technology stack comprises two proprietary platforms: CellProbe™ (CellsSort), an integrated antigen-specific single B cell manipulation and characterization platform that screens B cell repertoires from elite donors to identify rare, natively-paired therapeutic antibodies, and CellSeq™, a computational platform with ready-to-use modules (Abcloner, Abgermline, Ablineage, Absibling) for Sanger and NGS antibody sequence analysis. The therapeutic pipeline spans RSV (Phase I clinical stage), Pan-Ebolavirus CA45 (licensed from Integrated Biotherapeutics for development in China), a Staphylococcus aureus antibody cocktail (co-developed with Integrated Biotherapeutics for MRSA), and earlier-stage HBV, HCV, and neoantigen oncology programs.
The company's revenue model is hybrid and pre-monetization on the therapeutic side. It generates limited commercial revenue through EliteImmune Bioservices, a wholly-owned subsidiary offering contract antibody discovery campaigns, Ig-Seq analysis, antiviral assays (including SARS-CoV-2 variant pseudovirus neutralization), custom virus production, and unit-priced research reagents ($90 per Ebola VSV-pseudovirus; $99 per recombinant antigen or antibody). Future therapeutic revenue is intended to flow through licensing royalties and co-development partnerships with global pharmaceutical and biotechnology companies, supported by a dedicated business development function. The customer base spans biotech/pharma clients, academic institutions (University of Maryland, Wuhan University), and hospital research centers (Chenzhou No.1 People's Hospital), with Integrated Biotherapeutics serving as both the licensor of the CA45 asset and a co-development partner. Go-to-market relies on direct enterprise sales, scientific publications in top-tier journals (Cell, Nature Communications, Science), and a dual-channel web presence (corporate site and bioservices e-commerce portal).
EliteImmune firmographics
Firmographics- Name
- EliteImmune
- Legal name
- EliteImmune Corporation
- Website
- https://eliteimmune.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- EliteImmune is a private Gaithersburg, Maryland- and Tianjin, China-based biotechnology company that discovers broadly neutralizing antibody therapeutics for infectious diseases, oncology, and aging using its proprietary CellProbe™ and CellSeq™ single B cell screening and bioinformatics platforms, and monetizes those platforms through CRO services and reagent sales via its EliteImmune Bioservices subsidiary.
- Ownership category
- akta.pro rank
EliteImmune industry classification
Industry- Product category
- Biotechnology Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Medical and Diagnostic Laboratories (6215)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH)
Keywords
Where EliteImmune is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
EliteImmune business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain, Operations
Revenue model
- Therapeutic Antibody Development: Internal R&D programs developing antibody therapeutics for infectious diseases (Ebola, RSV, Staphylococcus), oncology, and aging. Pipeline includes lead discovery, preclinical, IND, and clinical phases. RSV therapeutic antibody currently in Phase I clinical trials.
- CRO Services - Antibody Discovery Campaigns: Contract research services for identifying lead antibody candidates against therapeutic targets from patient, non-human primate, or humanized mouse samples. Includes rational design of sample collection, screening strategies, and delivery of best-in-class natively-paired antibody panels.
- Ig-Seq Analysis Services: Online computational analysis tools and services for Sanger and next-generation antibody sequencing data using CellSeq™ platform modules (Abcloner, Abgermline, Ablineage, Absibling).
- Reagent Sales: Sale of research reagents including SARS RBD, ACE2, SARS-CoV-2 VSV-Pseudotype virus, SARS-VSV-Pseudotype virus, Ebola VSV-Pseudotype virus, recombinant antigens, and recombinant antibodies. Price points include $90/pc for Ebola pseudovirus and $99/pc for recombinant products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Ebola VSV-Pseudotype virus (Makona, Kivu) - research reagent |
| Unit Pricing | Pay-as-you-go | Recombinant antigen design and production - research reagent |
| Unit Pricing | Pay-as-you-go | Recombinant antibody production and purification - research reagent |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
EliteImmune product offering
Product offeringCore offering
EliteImmune develops antibody-based therapeutics for infectious diseases, oncology, and aging using its proprietary CellProbe™ single B cell screening and CellSeq™ computational antibody analysis platforms. In parallel, the company monetizes its discovery engine through CRO services — including custom antibody discovery campaigns, Ig-Seq analysis, antiviral/pseudovirus neutralization assays, custom virus production, and bioanalytical assays — and through catalog sales of research reagents (pseudoviruses, recombinant antigens, recombinant antibodies) via its EliteImmune Bioservices subsidiary.
Product overview
EliteImmune is a biotechnology company offering a unified platform of proprietary technologies and services for antibody therapeutics discovery. The core offerings include CellProbe™ (single B cell manipulation platform) and CellSeq™ (bioinformatics computational platform), supported by CRO services for antibody discovery campaigns, Ig-Seq analysis, antiviral assays, virus production, and featured reagents. The company maintains a pipeline of therapeutic antibody programs spanning infectious diseases (RSV, Ebola, HBV, HCV, MRSA/Staph) and oncology (neoantigen antibodies), with programs ranging from preclinical to Phase I clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- EliteImmune Bioservices: CRO services subsidiary offering antibody discovery campaigns, Ig-Seq analysis, antiviral assays, virus production, and research reagents through eliteimmunebioservices.com
Products and services
- Antibody Discovery Campaign
- Ig-Seq Analysis
- Antiviral Assays
- Virus Production
- Bioanalytical Assays
- Featured Reagents
Quantifiable outcome
- RSV therapeutic antibody in Phase I clinical trials
- +2 more outcomes
Companies that use EliteImmune
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
EliteImmune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
EliteImmune partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Integrated BiotherapeuticscoreCollaborative research agreement to identify and characterize novel monoclonal antibodies to Staphylococcus aureus (S. aureus) for therapeutic and diagnostic use. The two companies combine extensive expertise in bacterial toxins, antibody discovery, vaccines, and therapeutics. This follows their prior licensing agreement for Pan-Ebola antibody CA45.
- Integrated BiotherapeuticscoreExclusive licensing agreement for development of Pan-Ebola antibody CA45 in China. CA45 is a Pan-Ebola monoclonal antibody isolated by single B cell sorting, shown to fully protect non-human primates against live virus challenge. Further development may offer therapeutic and prophylactic protection against lethal Filoviruses.
- Reyoung Biopharmaceuticals (瑞阳生物制药)minorCollaborative partnership in antibody therapeutics development. Listed as a collaboration partner on the Science page.
- Zhenge Biotech (臻格生物)minorListed as a collaboration partner on the Science page, participating in the company's partnership ecosystem.
- Wuhan UniversityminorAcademic collaboration partner listed on the Science page for antibody discovery and development.
- Chenzhou No.1 People's HospitalminorClinical research collaboration partner listed on the Science page for antibody discovery and development.
- University of MarylandminorAcademic partnership including technology training (founder Dr. Ray Lei trained at University of Maryland-IBBR under Dr. Yuxing Li) and ongoing research collaborations.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
EliteImmune competitors and assessment
Company assessmentDirect peers
- Atreca: Clinical-stage biotech using proprietary immune repertoire analysis to discover antibody therapeutics — overlapping with EliteImmune's CellSeq™ and CellProbe™ approach of mining B cell repertoires from elite responders.
- Integral Molecular: Private antibody discovery company using proprietary technologies (including B cell screening platforms) to discover mAbs against membrane proteins and infectious disease targets. Comparable in platform-driven antibody discovery model and CRO offerings.
- Adimab: Private antibody discovery platform offering partnered discovery services to pharma/biotech with proprietary yeast-based screening. Directly comparable as a platform-first antibody company monetizing via partnerships rather than solely via internal pipeline.
- Sino Biological: China-headquartered reagent manufacturer and CRO offering recombinant proteins, antibodies, pseudovirus reagents, and CRO services. Highly comparable to EliteImmune's bioservices subsidiary, with overlapping product categories (recombinant antigens, pseudoviruses, antibodies at similar price points).
- AbCellera Biologics: Public antibody discovery platform company combining single-cell screening, AI/ML, and a CRO/services business with internal pipeline programs. Closest comparable in business model (platform + CRO + internal therapeutics) and underlying technology (high-throughput B cell screening).
Emerging players
- Harbour BioMed: Clinical-stage antibody therapeutics company with operations in both US and China, developing antibodies for oncology and infectious diseases (including HBV). Comparable dual US/China footprint and antibody pipeline focus, though broader in scope.
Broad incumbents
- GenScript ProBio: Global biologics CRO/CDMO offering antibody discovery, engineering, and manufacturing services. Comparable as a competitor in EliteImmune's CRO services business (EliteImmune Bioservices) and reagent/catalog offerings.
- WuXi Biologics: Global biologics CRO/CDMO offering end-to-end antibody discovery, development, and manufacturing. Comparable in CRO services scope and Chinese operational footprint; represents a much larger competitor in EliteImmune's bioservices market.
- Twist Bioscience: Public synthetic biology platform with antibody discovery services (Twist Biopharma) using library-based and AI-driven approaches. Comparable as a broader antibody platform competitor with CRO revenue and proprietary tools overlapping CellSeq™ functionality.
- Vir Biotechnology: Public clinical-stage infectious disease antibody company with approved product (sotrovimab) and pipeline across RSV, influenza, HBV, and HIV. Comparable in target indications (RSV, infectious disease antibodies) but operates at vastly greater scale and capital base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
EliteImmune social profiles
Digital presenceEliteImmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
EliteImmune leadership team
Management profileNumber of profiles
Profiles6 records
EliteImmune subsidiaries and ownership
Company hierarchySubsidiaries1 record
EliteImmune funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EliteImmune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EliteImmune
What does EliteImmune do?
EliteImmune develops antibody-based therapeutics for infectious diseases, oncology, and aging using its proprietary CellProbe™ single B cell screening and CellSeq™ computational antibody analysis platforms. In parallel, the company monetizes its discovery engine through CRO services — including custom antibody discovery campaigns, Ig-Seq analysis, antiviral/pseudovirus neutralization assays, custom virus production, and bioanalytical assays — and through catalog sales of research reagents (pseudoviruses, recombinant antigens, recombinant antibodies) via its EliteImmune Bioservices subsidiary.
Is EliteImmune a public or private company?
EliteImmune is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was EliteImmune founded?
EliteImmune was founded in 2019. It employs 1 to 10 people.
Where is EliteImmune based?
EliteImmune is headquartered in Gaithersburg, United States, in the North America region.
How does EliteImmune make money?
Four revenue lines are on record. Therapeutic Antibody Development is the primary driver. The others are CRO Services - Antibody Discovery Campaigns, ig-Seq Analysis Services and reagent Sales.
Who are EliteImmune's main competitors?
Direct peers on record are Atreca, Integral Molecular, Adimab, Sino Biological and AbCellera Biologics. Harbour BioMed is listed as an emerging player. Broad incumbents are GenScript ProBio, WuXi Biologics, Twist Bioscience and Vir Biotechnology.
Does EliteImmune have an API?
No public API is recorded for EliteImmune.
What industry is EliteImmune in?
EliteImmune's product category is Biotechnology Research Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 541714 and its SIC code is 2836.